Olga Nigro

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Alessio Cortellini, Marco Tucci, Vincenzo Adamo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 144 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone et al. · European Journal of Cancer · 2020 · 117 citations

Life Sciences, Immunology, Oncology +17

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 103 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacotherapy +12